The global paresthesia treatment market was valued at $5,376.28 million in 2021, and is projected to reach $7,900.0 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.
Paresthesia is numbness and a burning feeling that occurs most often in the extremities, such as the hands, arms, legs, or feet. It can occur elsewhere in the body as well. It is the same “pins and needles” feeling that happens when someone sits on their leg or foot for too long. It is caused when the nerves of arms and legs are under any kind of pressure. The discomfort goes away, once that pressure is relieved. Some people may have chronic paresthesia, which could be a sign of a more serious nerve injury or condition. Some of the causes of paresthesia include stroke, multiple sclerosis, tumor in the spinal cord or brain, high levels of vitamin D or other vitamins, diabetes, fibromyalgia, high blood pressure, infection, nerve injury, and compressed or pinched nerve. The symptoms of paresthesia include tingling or a “pins and needles” sensation, aching or burning pain, numbness or poor feeling in the affected area, a feeling that the affected area has “fallen asleep”, prickling or itching feeling, and hot or cold skin.
The global paresthesia treatment market is anticipated to show significant market growth during the forecast period, owing to rise in the prevalence of disease such as cancer, surge in geriatric population, and lack of proper nutrients in the food. Furthermore, increase in prevalence of paresthesia among the population, poor lifestyle, and surge in healthcare expenditure considerably contribute toward the market growth. However, low effectiveness of medicines associated with the treatment and stringent regulatory rules of the authority for the approvals of the medicines negatively impact the market growth. Conversely, the surge in investments in the research and developments (R&Ds) for better treatment offers lucrative opportunities for the growth of the market.
The paresthesia treatment market is segmented on the basis of disease type, treatment, distribution channel, and region. By disease type, the market is bifurcated into acute paresthesia and chronic paresthesia. Furthermore, the acute paresthesia is sub-classified as pediatric and adult. The chronic paresthesia segment is sub-classified as pediatric and adult. By treatment, the market is fragmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in the report include Abbott Laboratories, AbbVie Inc., Baxter International Inc., Bio-Medical Research Ltd., Boston Scientific Corporation, Cipla Ltd., Cyberonics, Inc., GlaxoSmithKline plc., Glenmark Pharmaceuticals, Medtronic plc, Merck KGaA, NeuroBo Pharmaceuticals, Inc., Nevro Corporation, Omron Healthcare, Inc. , Pfizer Inc., Reshape Lifesciences Inc., and Stimwave, LLC.
Paresthesia is numbness and a burning feeling that occurs most often in the extremities, such as the hands, arms, legs, or feet. It can occur elsewhere in the body as well. It is the same “pins and needles” feeling that happens when someone sits on their leg or foot for too long. It is caused when the nerves of arms and legs are under any kind of pressure. The discomfort goes away, once that pressure is relieved. Some people may have chronic paresthesia, which could be a sign of a more serious nerve injury or condition. Some of the causes of paresthesia include stroke, multiple sclerosis, tumor in the spinal cord or brain, high levels of vitamin D or other vitamins, diabetes, fibromyalgia, high blood pressure, infection, nerve injury, and compressed or pinched nerve. The symptoms of paresthesia include tingling or a “pins and needles” sensation, aching or burning pain, numbness or poor feeling in the affected area, a feeling that the affected area has “fallen asleep”, prickling or itching feeling, and hot or cold skin.
The global paresthesia treatment market is anticipated to show significant market growth during the forecast period, owing to rise in the prevalence of disease such as cancer, surge in geriatric population, and lack of proper nutrients in the food. Furthermore, increase in prevalence of paresthesia among the population, poor lifestyle, and surge in healthcare expenditure considerably contribute toward the market growth. However, low effectiveness of medicines associated with the treatment and stringent regulatory rules of the authority for the approvals of the medicines negatively impact the market growth. Conversely, the surge in investments in the research and developments (R&Ds) for better treatment offers lucrative opportunities for the growth of the market.
The paresthesia treatment market is segmented on the basis of disease type, treatment, distribution channel, and region. By disease type, the market is bifurcated into acute paresthesia and chronic paresthesia. Furthermore, the acute paresthesia is sub-classified as pediatric and adult. The chronic paresthesia segment is sub-classified as pediatric and adult. By treatment, the market is fragmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in the report include Abbott Laboratories, AbbVie Inc., Baxter International Inc., Bio-Medical Research Ltd., Boston Scientific Corporation, Cipla Ltd., Cyberonics, Inc., GlaxoSmithKline plc., Glenmark Pharmaceuticals, Medtronic plc, Merck KGaA, NeuroBo Pharmaceuticals, Inc., Nevro Corporation, Omron Healthcare, Inc. , Pfizer Inc., Reshape Lifesciences Inc., and Stimwave, LLC.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the paresthesia treatment market analysis from 2021 to 2031 to identify the prevailing paresthesia treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the paresthesia treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global paresthesia treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
- Acute Paresthesia
- Age Group
- Adult
- Geriatric
- Chronic Paresthesia
- Age Group
- Adult
- Geriatric
By Treatment
- Immunosuppressant
- Anticonvulsants
- Topical Creams
- Antivirals
- Others
By Distribution Channel
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Spain
- Rest of Europe
- France
- Germany
- UK
- Italy
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Turkey
- Venezuela
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- AbbVie Inc.
- Baxter International Inc.
- Bio-Medical Research Ltd.
- Boston Scientific Corporation
- Cipla Ltd.
- Cyberonics, Inc.
- EnteroMedics Inc.
- GlaxoSmithKline plc.
- Glenmark
- Medtronic
- Merck
- Nevro Corp.
- Omron Healthcare, Inc.
- Pfizer
- Stimwave LLC
- Stryker Corp.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: PARESTHESIA TREATMENT MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Acute Paresthesia
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Acute Paresthesia Paresthesia Treatment Market by Age Group
4.3 Chronic Paresthesia
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Chronic Paresthesia Paresthesia Treatment Market by Age Group
CHAPTER 5: PARESTHESIA TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Immunosuppressant
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Anticonvulsants
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Topical Creams
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Antivirals
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Others
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: PARESTHESIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: PARESTHESIA TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 France
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 Germany
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Taiwan
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.4.5.7 Rest Of Asia Pacific
7.4.5.7.1 Market size and forecast, by Disease Type
7.4.5.7.2 Market size and forecast, by Treatment
7.4.5.7.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Turkey
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 Venezuela
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Saudi Arabia
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Distribution Channel
7.5.5.5 South Africa
7.5.5.5.1 Market size and forecast, by Disease Type
7.5.5.5.2 Market size and forecast, by Treatment
7.5.5.5.3 Market size and forecast, by Distribution Channel
7.5.5.6 Rest of LAMEA
7.5.5.6.1 Market size and forecast, by Disease Type
7.5.5.6.2 Market size and forecast, by Treatment
7.5.5.6.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbott Laboratories
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AbbVie Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Baxter International Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bio-Medical Research Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Boston Scientific Corporation
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Cipla Ltd.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Cyberonics, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 EnteroMedics Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 GlaxoSmithKline plc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Glenmark
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Medtronic
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Merck
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Nevro Corp.
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Omron Healthcare, Inc.
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Pfizer
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Stimwave LLC
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Stryker Corp.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
Table 1. Global Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 2. Paresthesia Treatment Market Size, for Acute Paresthesia, by Region, 2021-2031 ($Million)
Table 3. Paresthesia Treatment Market for Acute Paresthesia, by Country, 2021-2031 ($Million)
Table 4. Global Acute Paresthesia Paresthesia Treatment Market, by Age Group, 2021-2031 ($Million)
Table 5. Paresthesia Treatment Market Size, for Chronic Paresthesia, by Region, 2021-2031 ($Million)
Table 6. Paresthesia Treatment Market for Chronic Paresthesia, by Country, 2021-2031 ($Million)
Table 7. Global Chronic Paresthesia Paresthesia Treatment Market, by Age Group, 2021-2031 ($Million)
Table 8. Global Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 9. Paresthesia Treatment Market Size, for Immunosuppressant, by Region, 2021-2031 ($Million)
Table 10. Paresthesia Treatment Market for Immunosuppressant, by Country, 2021-2031 ($Million)
Table 11. Paresthesia Treatment Market Size, for Anticonvulsants, by Region, 2021-2031 ($Million)
Table 12. Paresthesia Treatment Market for Anticonvulsants, by Country, 2021-2031 ($Million)
Table 13. Paresthesia Treatment Market Size, for Topical Creams, by Region, 2021-2031 ($Million)
Table 14. Paresthesia Treatment Market for Topical Creams, by Country, 2021-2031 ($Million)
Table 15. Paresthesia Treatment Market Size, for Antivirals, by Region, 2021-2031 ($Million)
Table 16. Paresthesia Treatment Market for Antivirals, by Country, 2021-2031 ($Million)
Table 17. Paresthesia Treatment Market Size, for Others, by Region, 2021-2031 ($Million)
Table 18. Paresthesia Treatment Market for Others, by Country, 2021-2031 ($Million)
Table 19. Global Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 20. Paresthesia Treatment Market Size, for Hospital Pharmacy, by Region, 2021-2031 ($Million)
Table 21. Paresthesia Treatment Market for Hospital Pharmacy, by Country, 2021-2031 ($Million)
Table 22. Paresthesia Treatment Market Size, for Retail Pharmacy, by Region, 2021-2031 ($Million)
Table 23. Paresthesia Treatment Market for Retail Pharmacy, by Country, 2021-2031 ($Million)
Table 24. Paresthesia Treatment Market Size, for Online Pharmacy, by Region, 2021-2031 ($Million)
Table 25. Paresthesia Treatment Market for Online Pharmacy, by Country, 2021-2031 ($Million)
Table 26. Paresthesia Treatment Market, by Region, 2021-2031 ($Million)
Table 27. North America Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 28. North America Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 29. North America Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 30. North America Paresthesia Treatment Market, by Country, 2021-2031 ($Million)
Table 31. U.S. Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 32. U.S. Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 33. U.S. Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 34. Canada Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 35. Canada Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 36. Canada Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 37. Mexico Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 38. Mexico Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 39. Mexico Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 40. Europe Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 41. Europe Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 42. Europe Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 43. Europe Paresthesia Treatment Market, by Country, 2021-2031 ($Million)
Table 44. France Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 45. France Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 46. France Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 47. Germany Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 48. Germany Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 49. Germany Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 50. UK Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 51. UK Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 52. UK Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 53. Italy Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 54. Italy Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 55. Italy Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 56. Spain Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 57. Spain Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 58. Spain Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 59. Rest of Europe Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 60. Rest of Europe Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 61. Rest of Europe Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 62. Asia-Pacific Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 63. Asia-Pacific Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 64. Asia-Pacific Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 65. Asia-Pacific Paresthesia Treatment Market, by Country, 2021-2031 ($Million)
Table 66. Japan Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 67. Japan Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 68. Japan Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 69. China Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 70. China Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 71. China Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 72. India Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 73. India Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 74. India Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 75. Australia Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 76. Australia Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 77. Australia Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 78. South Korea Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 79. South Korea Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 80. South Korea Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 81. Taiwan Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 82. Taiwan Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 83. Taiwan Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 84. Rest of Asia-Pacific Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 85. Rest of Asia-Pacific Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 86. Rest of Asia-Pacific Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 87. LAMEA Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 88. LAMEA Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 89. LAMEA Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 90. LAMEA Paresthesia Treatment Market, by Country, 2021-2031 ($Million)
Table 91. Brazil Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 92. Brazil Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 93. Brazil Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 94. Turkey Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 95. Turkey Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 96. Turkey Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 97. Venezuela Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 98. Venezuela Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 99. Venezuela Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 100. Saudi Arabia Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 101. Saudi Arabia Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 102. Saudi Arabia Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 103. South Africa Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 104. South Africa Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 105. South Africa Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 106. Rest of LAMEA Paresthesia Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 107. Rest of LAMEA Paresthesia Treatment Market, by Treatment, 2021-2031 ($Million)
Table 108. Rest of LAMEA Paresthesia Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 109. Abbott Laboratories: Company Snapshot
Table 110. Abbott Laboratories: Operating Segments
Table 111. Abbott Laboratories: Product Portfolio
Table 112. Abbott Laboratories: Net Sales
Table 113. Abbott Laboratories: Key Strategies
Table 114. Abbvie Inc.: Company Snapshot
Table 115. Abbvie Inc.: Operating Segments
Table 116. Abbvie Inc.: Product Portfolio
Table 117. Abbvie Inc.: Net Sales
Table 118. Abbvie Inc.: Key Strategies
Table 119. Baxter International Inc.: Company Snapshot
Table 120. Baxter International Inc.: Operating Segments
Table 121. Baxter International Inc.: Product Portfolio
Table 122. Baxter International Inc.: Net Sales
Table 123. Baxter International Inc.: Key Strategies
Table 124. Bio-Medical Research Ltd.: Company Snapshot
Table 125. Bio-Medical Research Ltd.: Operating Segments
Table 126. Bio-Medical Research Ltd.: Product Portfolio
Table 127. Bio-Medical Research Ltd.: Net Sales
Table 128. Bio-Medical Research Ltd.: Key Strategies
Table 129. Boston Scientific Corporation: Company Snapshot
Table 130. Boston Scientific Corporation: Operating Segments
Table 131. Boston Scientific Corporation: Product Portfolio
Table 132. Boston Scientific Corporation: Net Sales
Table 133. Boston Scientific Corporation: Key Strategies
Table 134. Cipla Ltd.: Company Snapshot
Table 135. Cipla Ltd.: Operating Segments
Table 136. Cipla Ltd.: Product Portfolio
Table 137. Cipla Ltd.: Net Sales
Table 138. Cipla Ltd.: Key Strategies
Table 139. Cyberonics, Inc.: Company Snapshot
Table 140. Cyberonics, Inc.: Operating Segments
Table 141. Cyberonics, Inc.: Product Portfolio
Table 142. Cyberonics, Inc.: Net Sales
Table 143. Cyberonics, Inc.: Key Strategies
Table 144. Enteromedics Inc.: Company Snapshot
Table 145. Enteromedics Inc.: Operating Segments
Table 146. Enteromedics Inc.: Product Portfolio
Table 147. Enteromedics Inc.: Net Sales
Table 148. Enteromedics Inc.: Key Strategies
Table 149. GlaxoSmithKline PLC.: Company Snapshot
Table 150. GlaxoSmithKline PLC.: Operating Segments
Table 151. GlaxoSmithKline PLC.: Product Portfolio
Table 152. GlaxoSmithKline PLC.: Net Sales
Table 153. GlaxoSmithKline PLC.: Key Strategies
Table 154. Glenmark: Company Snapshot
Table 155. Glenmark: Operating Segments
Table 156. Glenmark: Product Portfolio
Table 157. Glenmark: Net Sales
Table 158. Glenmark: Key Strategies
Table 159. Medtronic: Company Snapshot
Table 160. Medtronic: Operating Segments
Table 161. Medtronic: Product Portfolio
Table 162. Medtronic: Net Sales
Table 163. Medtronic: Key Strategies
Table 164. Merck: Company Snapshot
Table 165. Merck: Operating Segments
Table 166. Merck: Product Portfolio
Table 167. Merck: Net Sales
Table 168. Merck: Key Strategies
Table 169. Nevro Corp.: Company Snapshot
Table 170. Nevro Corp.: Operating Segments
Table 171. Nevro Corp.: Product Portfolio
Table 172. Nevro Corp.: Net Sales
Table 173. Nevro Corp.: Key Strategies
Table 174. Omron Healthcare, Inc.: Company Snapshot
Table 175. Omron Healthcare, Inc.: Operating Segments
Table 176. Omron Healthcare, Inc.: Product Portfolio
Table 177. Omron Healthcare, Inc.: Net Sales
Table 178. Omron Healthcare, Inc.: Key Strategies
Table 179. Pfizer: Company Snapshot
Table 180. Pfizer: Operating Segments
Table 181. Pfizer: Product Portfolio
Table 182. Pfizer: Net Sales
Table 183. Pfizer: Key Strategies
Table 184. Stimwave LLC: Company Snapshot
Table 185. Stimwave LLC: Operating Segments
Table 186. Stimwave LLC: Product Portfolio
Table 187. Stimwave LLC: Net Sales
Table 188. Stimwave LLC: Key Strategies
Table 189. Stryker Corp.: Company Snapshot
Table 190. Stryker Corp.: Operating Segments
Table 191. Stryker Corp.: Product Portfolio
Table 192. Stryker Corp.: Net Sales
Table 193. Stryker Corp.: Key Strategies
List of Figures
Figure 1. Paresthesia Treatment Market Segmentation
Figure 2. Paresthesia Treatment Market, 2021-2031
Figure 3. Paresthesia Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Paresthesia Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Paresthesia Treatment Market, By Disease Type, 2021(%)
Figure 13. Comparative Share Analysis of Acute Paresthesia Paresthesia Treatment Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of Chronic Paresthesia Paresthesia Treatment Market, 2021-2031(%)
Figure 15. Paresthesia Treatment Market, By Treatment, 2021(%)
Figure 16. Comparative Share Analysis of Immunosuppressant Paresthesia Treatment Market, 2021-2031(%)
Figure 17. Comparative Share Analysis of Anticonvulsants Paresthesia Treatment Market, 2021-2031(%)
Figure 18. Comparative Share Analysis of Topical Creams Paresthesia Treatment Market, 2021-2031(%)
Figure 19. Comparative Share Analysis of Antivirals Paresthesia Treatment Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Others Paresthesia Treatment Market, 2021-2031(%)
Figure 21. Paresthesia Treatment Market, By Distribution Channel, 2021(%)
Figure 22. Comparative Share Analysis of Hospital Pharmacy Paresthesia Treatment Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Retail Pharmacy Paresthesia Treatment Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Online Pharmacy Paresthesia Treatment Market, 2021-2031(%)
Figure 25. Paresthesia Treatment Market by Region, 2021
Figure 26. U.S. Paresthesia Treatment Market, 2021-2031($Million)
Figure 27. Canada Paresthesia Treatment Market, 2021-2031($Million)
Figure 28. Mexico Paresthesia Treatment Market, 2021-2031($Million)
Figure 29. France Paresthesia Treatment Market, 2021-2031($Million)
Figure 30. Germany Paresthesia Treatment Market, 2021-2031($Million)
Figure 31. Uk Paresthesia Treatment Market, 2021-2031($Million)
Figure 32. Italy Paresthesia Treatment Market, 2021-2031($Million)
Figure 33. Spain Paresthesia Treatment Market, 2021-2031($Million)
Figure 34. Rest of Europe Paresthesia Treatment Market, 2021-2031($Million)
Figure 35. Japan Paresthesia Treatment Market, 2021-2031($Million)
Figure 36. China Paresthesia Treatment Market, 2021-2031($Million)
Figure 37. India Paresthesia Treatment Market, 2021-2031($Million)
Figure 38. Australia Paresthesia Treatment Market, 2021-2031($Million)
Figure 39. South Korea Paresthesia Treatment Market, 2021-2031($Million)
Figure 40. Taiwan Paresthesia Treatment Market, 2021-2031($Million)
Figure 41. Rest of Asia-Pacific Paresthesia Treatment Market, 2021-2031($Million)
Figure 42. Brazil Paresthesia Treatment Market, 2021-2031($Million)
Figure 43. Turkey Paresthesia Treatment Market, 2021-2031($Million)
Figure 44. Venezuela Paresthesia Treatment Market, 2021-2031($Million)
Figure 45. Saudi Arabia Paresthesia Treatment Market, 2021-2031($Million)
Figure 46. South Africa Paresthesia Treatment Market, 2021-2031($Million)
Figure 47. Rest of LAMEA Paresthesia Treatment Market, 2021-2031($Million)
Figure 48. Top Winning Strategies, by Year
Figure 49. Top Winning Strategies, by Development
Figure 50. Top Winning Strategies, by Company
Figure 51. Product Mapping of Top 10 Players
Figure 52. Competitive Dashboard
Figure 53. Competitive Heatmap of Top 10 Key Players
Figure 54. Abbott Laboratorie.: Net Sales, ($Million)
Figure 55. Abbvie Inc.: Net Sales, ($Million)
Figure 56. Baxter International Inc.: Net Sales, ($Million)
Figure 57. Bio-Medical Research Ltd.: Net Sales, ($Million)
Figure 58. Boston Scientific Corporatio.: Net Sales, ($Million)
Figure 59. Cipla Ltd.: Net Sales, ($Million)
Figure 60. Cyberonics, Inc.: Net Sales, ($Million)
Figure 61. Enteromedics Inc.: Net Sales, ($Million)
Figure 62. GlaxoSmithKline plc.: Net Sales, ($Million)
Figure 63. Glenmar.: Net Sales, ($Million)
Figure 64. Medtroni.: Net Sales, ($Million)
Figure 65. Merc.: Net Sales, ($Million)
Figure 66. Nevro Corp.: Net Sales, ($Million)
Figure 67. Omron Healthcare, Inc.: Net Sales, ($Million)
Figure 68. Pfize.: Net Sales, ($Million)
Figure 69. Stimwave LL.: Net Sales, ($Million)
Figure 70. Stryker Corp.: Net Sales, ($Million)
Executive Summary
According to the report, “Paresthesia Treatment Market," the paresthesia treatment market size was valued at $5.4 billion in 2021, and is estimated to reach $7.9 billion by 2031, growing at a CAGR of 3.8% from 2022 to 2031.Paresthesia is that "pins and needles" feeling that may have been felt probably at some point. Maybe one fell asleep with the arm pinned under body or may have kept the legs crossed too long. It commonly affects the body parts such as hands, arms, legs, and feet. The paresthesia treatment market analysis include the growth trends like surge in geriatric population, rise in prevalence of cancer, and higher number of R&D activities to develop treatment therapeutics that have significantly contributed toward the growth of the market. Promising drugs in late stage of pipeline with high potential of emerging economies are further expected to provide lucrative opportunities for growth of paresthesia treatment market size. However, low effectiveness of medicines associated with the treatment impede the paresthesia treatment industry growth.
By disease type, the acute paresthesia segment is projected to exhibit the fastest market growth of 4.8% during the forecast period due to the paresthesia treatment market trends like increase in the incidences of acute paresthesia and expected launch of pipeline immunotherapies.
By treatment, The antivirals segment is projected to exhibit the fastest market growth of 4.5% during the forecast period, owing to rise in geriatric population, increase in study of usage of antivirals in teatment of paresthesia, and surge in efficacy of medicines & advantages related to the its usage.
By distribution channel, the online pharmacy segment is projected to exhibit the fastest market growth of 5.5% during the forecast period, owing to rise in preference of the people for buying the products from online platforms at the comfort of their home.
Asia-Pacific region is expected to grow with the highest CAGR, owing to increase in number of affected population and rise in awareness related to different types of paresthesia.
KEY FINDINGS OF STUDY
- By disease type, the chronic paresthesia segment accounted for major paresthesia treatment market share in 2021.
- By treatment, the antivirals segment is anticipated to grow with the highest CAGR throughout the forecast period.
- By distribution channel, retail pharmacy segment occupied major share of the paresthesia treatment industry in 2021.
- Asia-Pacific is anticipated to grow at the highest rate during the paresthesia treatment market forecast period.
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc.
- Baxter International Inc.
- Bio-Medical Research Ltd.
- Boston Scientific Corporation
- Cipla Ltd.
- Cyberonics, Inc.
- EnteroMedics Inc.
- GlaxoSmithKline plc.
- Glenmark
- Medtronic
- Merck
- Nevro Corp.
- Omron Healthcare, Inc.
- Pfizer
- Stimwave LLC
- Stryker Corp.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 328 |
| Published | September 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 5376.28 million |
| Forecasted Market Value ( USD | $ 7900 million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
